Threshold dose for peanut: Risk characterization based upon diagnostic oral challenge of a series of 286 peanut-allergic individuals
Abstract
Clinical records of 286 consecutive patients reacting positively with objective symptoms to double-blind, placebo-controlled oral peanut challenges at University Hospital, Nancy, France were examined for individual No Observed Adverse Effect Levels (NOAELs) and Lowest Observed Adverse Effect Levels (LOAELs). After fitting to a log-normal probability distribution model, the ED(10) and ED(05) were 14.4 and 7.3mg (expressed as whole peanut), respectively, with 95% lower confidence intervals of 10.7 and 5.2mg, respectively. Compared to results from a previous study where the ED(10) was based upon individual peanut thresholds gleaned from 12 publications, a statistically significant difference was observed between the ED(50)'s, but not the ED(10)'s of the two probability distribution curves. The Nancy patient group contains more sensitive subjects than the group from the published literature thus contributing to the observed differences. Minimum eliciting dose-distributions for patients with histories of more severe reactions (grade 4 or 5; 40 subjects) did not differ significantly from those of patients with histories of less severe reactions (grades 1-3; 123 subjects). These data and this modeling approach could be used to establish population thresholds for peanut-allergic consumers and thereby provide a sound basis for allergen control measures in the food industry.
Related
- Dynamic Responses to an Inflammatory Challenge Distinguish Metabolic Health Across Lean and Obese Individuals
- Diagnostic challenge in veterinary pathology: Late term abortion in a cow
- A Diagnostic Challenge in Linear Dermatoses: Differentiating Inflammatory Linear Verrucous Epidermal Nevus (ILVEN) Using Dermoscopy and Reflectance Confocal Microscopy-A Case Report.
- Diagnostic Challenge of Crohn’s Disease in a Patient with Clinically Diagnosed Pulmonary Tuberculosis: A Case Report
- Indirect Estimation of the First Ventilatory Threshold in Beta-Blocked Cardiac Patients: A Diagnostic Accuracy Study
BibTeX
@article{taylor2026threshold,
title = {{Threshold dose for peanut: Risk characterization based upon diagnostic oral challenge of a series of 286 peanut-allergic individuals}},
author = {Steve Taylor and D.A. Moneret-Vautrin and Rene W.R. Crevel and David Sheffield and Martine Morisset and P. Dumont and Benjamin Remington and Joseph Baumert},
journal = {Food and Chemical Toxicology},
year = {2026},
month = oct,
doi = {10.1016/j.fct.2009.12.013},
url = {https://hal.science/hal-05780008v1},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Threshold dose for peanut: Risk characterization based upon diagnostic oral challenge of a series of 286 peanut-allergic individuals
AU - Steve Taylor
AU - D.A. Moneret-Vautrin
AU - Rene W.R. Crevel
AU - David Sheffield
AU - Martine Morisset
AU - P. Dumont
AU - Benjamin Remington
AU - Joseph Baumert
PY - 2026
DA - 2026/10/06
JO - Food and Chemical Toxicology
DO - 10.1016/j.fct.2009.12.013
UR - https://hal.science/hal-05780008v1
AB - Clinical records of 286 consecutive patients reacting positively with objective symptoms to double-blind, placebo-controlled oral peanut challenges at University Hospital, Nancy, France were examined for individual No Observed Adverse Effect Levels (NOAELs) and Lowest Observed Adverse Effect Levels (LOAELs). After fitting to a log-normal probability distribution model, the ED(10) and ED(05) were 14.4 and 7.3mg (expressed as whole peanut), respectively, with 95% lower confidence intervals of 10.7 and 5.2mg, respectively. Compared to results from a previous study where the ED(10) was based upon individual peanut thresholds gleaned from 12 publications, a statistically significant difference was observed between the ED(50)'s, but not the ED(10)'s of the two probability distribution curves. The Nancy patient group contains more sensitive subjects than the group from the published literature thus contributing to the observed differences. Minimum eliciting dose-distributions for patients with histories of more severe reactions (grade 4 or 5; 40 subjects) did not differ significantly from those of patients with histories of less severe reactions (grades 1-3; 123 subjects). These data and this modeling approach could be used to establish population thresholds for peanut-allergic consumers and thereby provide a sound basis for allergen control measures in the food industry.
SN - 0278-6915
ER -